Pembrolizumab Addition Improves Clinical Response in HER2+ Gastric Cancer

Skip Nav Destination

Article navigation

Research Watch| February 09 2022

Pembrolizumab Addition Improves Clinical Response in HER2⁺ Gastric Cancer

Online Issn: 2159-8290

Print Issn: 2159-8274

2022

American Association for Cancer Research.

Cancer Discov (2022) 12 (2): 289.

Addition of pembrolizumab to trastuzumab/chemotherapy reduces tumor size and can induce complete response.

2022

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.